دورية أكاديمية
Crosstalk between breast cancer-derived microRNAs and brain microenvironmental cells in breast cancer brain metastasis.
| العنوان: | Crosstalk between breast cancer-derived microRNAs and brain microenvironmental cells in breast cancer brain metastasis. |
|---|---|
| المؤلفون: | Khan MS; Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, United States., Wong GL; Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, United States., Zhuang C; Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, United States., Najjar MK; Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, United States., Lo HW; Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, United States.; Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States. |
| المصدر: | Frontiers in oncology [Front Oncol] 2024 Aug 08; Vol. 14, pp. 1436942. Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Breast cancer is the most frequent malignancy in women, constituting 15.2% of all new cancers diagnosed in the United States. Distant breast cancer metastasis accounts for the majority of breast cancer-related deaths; brain metastasis is the third most common site for metastatic breast cancer but is associated with worst prognosis of approximately eight months of survival. Current treatment options for breast cancer brain metastasis (BCBM) are limited and ineffective. To help identify new and effective therapies for BCBM, it is important to investigate the mechanisms by which breast cancer cells metastasize to the brain and thrive in the brain microenvironment. To this end, studies have reported that primary breast tumor cells can prime brain microenvironmental cells, including, astrocytes and microglia, to promote the formation of BCBM through the release of extracellular vesicle-microRNAs (miRNAs). Breast tumor-derived miRNAs can also promote breast cancer cell invasion through the blood-brain barrier by disrupting the integrity of the brain microvascular endothelial cells. In this review, we summarize current literature on breast cancer-derived BCBM-promoting miRNAs, cover their roles in the complex steps of BCBM particularly their interactions with microenvironmental cells within the brain metastatic niche, and finally discuss their therapeutic applications in the management of BCBM. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Khan, Wong, Zhuang, Najjar and Lo.) |
| References: | J Cereb Blood Flow Metab. 2016 Sep;36(9):1481-507. (PMID: 27323783) Oncogene. 2021 Mar;40(9):1737-1751. (PMID: 33536579) Oncogene. 2012 Sep 13;31(37):4150-63. (PMID: 22158050) Cancer Lett. 2024 Jan 28;581:216508. (PMID: 38029538) PLoS One. 2012;7(7):e41170. (PMID: 22829924) Br J Cancer. 2020 May;122(11):1630-1637. (PMID: 32238921) Am J Transl Res. 2014 Jul 18;6(4):384-90. (PMID: 25075255) J Immunol. 2012 Jul 1;189(1):444-53. (PMID: 22664874) J Natl Cancer Inst. 2016 Apr 13;108(8):. (PMID: 27075851) Cell. 2008 May 16;133(4):704-15. (PMID: 18485877) Nat Rev Clin Oncol. 2021 Nov;18(11):696-714. (PMID: 34253912) Nat Struct Mol Biol. 2015 Jan;22(1):20-8. (PMID: 25565029) Front Genet. 2019 May 16;10:478. (PMID: 31156715) Int J Mol Sci. 2023 Aug 28;24(17):. (PMID: 37686149) Neoplasia. 2011 Mar;13(3):286-98. (PMID: 21390191) PLoS One. 2012;7(3):e30679. (PMID: 22427800) Nat Rev Cancer. 2012 May 11;12(6):425-36. (PMID: 22576165) NPJ Precis Oncol. 2018 Feb 16;2(1):4. (PMID: 29872722) PLoS One. 2020 Oct 1;15(10):e0239292. (PMID: 33002044) Clin Chem. 2010 Nov;56(11):1733-41. (PMID: 20847327) Oncogene. 2015 Sep 10;34(37):4890-900. (PMID: 25659578) Sci Rep. 2016 Oct 21;6:35642. (PMID: 27767041) Mol Biol Rep. 2019 Apr;46(2):1787-1796. (PMID: 30707415) J Cell Physiol. 2019 Jun;234(6):9816-9825. (PMID: 30480817) Nature. 2015 Nov 5;527(7576):100-104. (PMID: 26479035) Nat Commun. 2022 Nov 2;13(1):6581. (PMID: 36323693) Cell. 2013 Dec 19;155(7):1568-80. (PMID: 24360278) Sci Rep. 2016 Oct 05;6:34504. (PMID: 27703260) Nature. 2004 Nov 11;432(7014):231-5. (PMID: 15531879) Nat Biotechnol. 2013 Jul;31(7):577. (PMID: 23839128) Cell Oncol (Dordr). 2017 Oct;40(5):457-470. (PMID: 28741069) Neuro Oncol. 2014 Apr;16(4):540-51. (PMID: 24311639) PLoS One. 2019 Apr 22;14(4):e0215894. (PMID: 31009516) Cancer Cell. 2011 Jan 18;19(1):125-37. (PMID: 21251616) Gene. 2012 Oct 10;507(2):135-8. (PMID: 22842193) Cancer Lett. 2014 Nov 28;354(2):455-66. (PMID: 25149066) Mol Med Rep. 2015 Sep;12(3):4647-4651. (PMID: 26080894) Autophagy. 2017;13(11):1905-1923. (PMID: 28981380) Neuro Oncol. 2021 Jun 1;23(6):894-904. (PMID: 33367836) Breast Cancer Res. 2013;15(4):R54. (PMID: 23826634) Nature. 2010 Jun 3;465(7298):584-9. (PMID: 20424607) Cancer Res. 2018 Aug 1;78(15):4316-4330. (PMID: 30026327) Sci Rep. 2016 Jun 23;6:28587. (PMID: 27335258) Am J Pathol. 2012 Jun;180(6):2490-503. (PMID: 22521303) Br J Cancer. 2014 Mar 18;110(6):1497-505. (PMID: 24569463) Cell. 1993 Dec 3;75(5):843-54. (PMID: 8252621) Cancer Cell. 2014 Apr 14;25(4):501-15. (PMID: 24735924) Sci Rep. 2019 Dec 6;9(1):18518. (PMID: 31811234) Int J Mol Sci. 2021 May 14;22(10):. (PMID: 34069135) ScientificWorldJournal. 2008 Sep 21;8:901-4. (PMID: 18836656) Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14879-84. (PMID: 18812516) Clin Dev Immunol. 2013;2013:285246. (PMID: 23983766) Breast Cancer Res. 2017 Apr 26;19(1):51. (PMID: 28446206) Mol Pharmacol. 2009 Jun;75(6):1374-9. (PMID: 19270061) Eur J Heart Fail. 2024 Mar;26(3):674-682. (PMID: 38269451) Cell Death Dis. 2018 Jan 11;9(1):14. (PMID: 29323124) CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. (PMID: 38230766) Cold Spring Harb Perspect Biol. 2015 Jan 05;7(1):a020412. (PMID: 25561720) J Clin Neurosci. 2015 Mar;22(3):570-4. (PMID: 25487174) J Biol Chem. 2015 Apr 10;290(15):9842-54. (PMID: 25691572) Genes Dev. 2008 Apr 1;22(7):894-907. (PMID: 18381893) Cancer Res. 2021 Feb 1;81(3):594-605. (PMID: 33526470) Cancer Res. 2008 Sep 15;68(18):7613-20. (PMID: 18794150) Nat Neurosci. 2016 May 26;19(6):771-83. (PMID: 27227366) J Neurosci. 2013 Apr 17;33(16):6857-63. (PMID: 23595744) Neuro Oncol. 2012 Jun;14(6):689-700. (PMID: 22492962) J Transl Med. 2018 Feb 23;16(1):38. (PMID: 29471858) Nature. 2012 Sep 6;489(7414):57-74. (PMID: 22955616) PLoS One. 2013 Nov 12;8(11):e79467. (PMID: 24265774) Mol Cancer Res. 2011 Nov;9(11):1500-8. (PMID: 21875932) Mol Cell Biol. 2012 Feb;32(3):633-51. (PMID: 22144583) Cancer Lett. 2008 Dec 18;272(2):177-85. (PMID: 18579285) Oncotarget. 2015 May 20;6(14):12188-95. (PMID: 25893380) Signal Transduct Target Ther. 2023 May 25;8(1):217. (PMID: 37231000) Cancer Metastasis Rev. 2012 Dec;31(3-4):469-78. (PMID: 22729277) Signal Transduct Target Ther. 2016 Jan 28;1:15004. (PMID: 29263891) Nature. 1998 Feb 19;391(6669):806-11. (PMID: 9486653) Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4203-8. (PMID: 24586048) Cancer Res. 2014 Sep 1;74(17):4937-45. (PMID: 24970480) Nat Rev Genet. 2011 Feb;12(2):99-110. (PMID: 21245828) Neuro Oncol. 2013 Jul;15(7):891-903. (PMID: 23595625) Nat Rev Cancer. 2013 Feb;13(2):97-110. (PMID: 23344542) Science. 2009 Nov 27;326(5957):1275-9. (PMID: 19965479) Nat Rev Genet. 2008 Feb;9(2):102-14. (PMID: 18197166) Cell. 2005 Jan 14;120(1):15-20. (PMID: 15652477) Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. (PMID: 12434020) Ann Oncol. 2014 Nov;25(11):2230-2236. (PMID: 25081901) Breast Cancer Res Treat. 2013 Jun;139(3):717-30. (PMID: 23780685) Nature. 2004 Sep 16;431(7006):350-5. (PMID: 15372042) Cancer Res. 2011 Feb 1;71(3):645-54. (PMID: 21266359) Nat Cell Biol. 2015 Feb;17(2):183-94. (PMID: 25621950) Breast Cancer (Dove Med Press). 2022 Aug 01;14:187-198. (PMID: 35936987) Pharmaceuticals (Basel). 2020 Jul 07;13(7):. (PMID: 32645833) Nature. 2016 May 18;533(7604):493-498. (PMID: 27225120) J Cell Sci. 2010 Feb 1;123(Pt 3):431-40. (PMID: 20067998) Wound Repair Regen. 2018 Jul;26(4):311-323. (PMID: 30118158) Int J Mol Sci. 2017 Jun 24;18(7):. (PMID: 28672801) Nat Cell Biol. 2008 May;10(5):593-601. (PMID: 18376396) Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15163-8. (PMID: 20699384) J Clin Oncol. 2004 Jul 15;22(14):2865-72. (PMID: 15254054) PLoS One. 2012;7(7):e42012. (PMID: 22848689) Carcinogenesis. 2019 Aug 22;40(8):1010-1020. (PMID: 30605519) Cancer Lett. 2022 Aug 1;540:215726. (PMID: 35589002) Genes Dev. 2004 Dec 15;18(24):3016-27. (PMID: 15574589) Cancer Sci. 2018 May;109(5):1404-1413. (PMID: 29575368) Mol Oncol. 2020 Mar;14(3):520-538. (PMID: 31930767) Nat Commun. 2015 Apr 01;6:6716. (PMID: 25828099) Cancer Res. 2013 Feb 15;73(4):1434-44. (PMID: 23384942) Biol Pharm Bull. 2023;46(10):1353-1364. (PMID: 37779037) Cancer Microenviron. 2012 Apr;5(1):19-28. (PMID: 21892699) Nature. 2015 Mar 26;519(7544):482-5. (PMID: 25799998) Neuro Oncol. 2014 Dec;16(12):1585-98. (PMID: 25008093) Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143. (PMID: 28918016) Cell. 2014 Feb 27;156(5):1002-16. (PMID: 24581498) Cancer Lett. 2020 Jul 1;481:24-31. (PMID: 32246957) J Transl Med. 2012 Mar 08;10:42. (PMID: 22400902) Oncotarget. 2015 Aug 28;6(25):20829-39. (PMID: 26246487) |
| معلومات مُعتمدة: | R01 CA228137 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: blood-brain barrier; brain metastasis; brain microenvironment; breast cancer; microRNA |
| تواريخ الأحداث: | Date Created: 20240823 Latest Revision: 20240830 |
| رمز التحديث: | 20240830 |
| مُعرف محوري في PubMed: | PMC11338853 |
| DOI: | 10.3389/fonc.2024.1436942 |
| PMID: | 39175471 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2024.1436942 |